EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan

Koto Kawata, Hajime Otsu, Takaaki Masuda, Taro Tobo, Yoshiki Hiraki, Qingjiang Hu, Yusuke Yonemura, Koji Ando, Koshi Mimori, Tomoharu Yoshizumi

Annals of Gastroenterological Surgery · 2027-01 · 11 (1)

DOI: 10.1002/ags3.70303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Gastroenterological Surgery, online erschienen am 18.11.2026. Verfasst von Koto Kawata und 9 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim Colorectal cancer (CRC) is a leading cause of cancer‐related mortality worldwide. This study aimed to identify tumor‐associated genes in CRC and explore potential therapeutic agents by analyzing chromosomal amplification.

Methods

DNA copy number variation (CNV) and mRNA expression data from The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) were analyzed. We focused on cytochrome c oxidase assembly factor 19 (COX19) as a candidate tumor‐associated gene and examined its clinicopathological and prognostic relevance. Single‐cell RNA sequencing and immunohistochemical analyses were performed. Pathway and drug sensitivity analyses were conducted, followed by in vitro validation of candidate compounds.

Results

COX19, a mitochondrial complex IV assembly factor, was significantly amplified and overexpressed in CRC. High COX19 expression correlated with poor prognosis and was predominantly observed in tumor epithelial cells. Gene set enrichment analysis (GSEA) suggested suppression of apoptosis in COX19 ‐high tumors. Drug sensitivity analysis identified olmesartan as a candidate therapeutic agent. Olmesartan suppressed the proliferative capacity of COX19 ‐overexpressing CRC cells, whereas COX19 knockout reduced sensitivity to olmesartan. Olmesartan also increased miR‐205‐3p expression, and miR‐205‐3p inhibition partially attenuated its antiproliferative effect.

Conclusion

COX19 may be a tumor‐associated gene linked to tumor progression and poor prognosis in CRC. Olmesartan may represent a potential therapeutic candidate for COX19 ‐high CRC. Its antiproliferative effects may involve miR‐205‐3p, although the underlying mechanism requires further validation.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kawata, K., Otsu, H., Masuda, T., Tobo, T., Hiraki, Y., Hu, Q., Yonemura, Y., Ando, K., Mimori, K., & Yoshizumi, T. (2027). Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan. Annals of Gastroenterological Surgery, 11(1). https://doi.org/10.1002/ags3.70303

Vancouver

Kawata K, Otsu H, Masuda T, Tobo T, Hiraki Y, Hu Q, et al. Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan. Annals of Gastroenterological Surgery. 2027;11(1). doi:10.1002/ags3.70303

BibTeX
@article{Kawata2027,
  author = {Kawata, Koto and Otsu, Hajime and Masuda, Takaaki and Tobo, Taro and Hiraki, Yoshiki and Hu, Qingjiang and Yonemura, Yusuke and Ando, Koji and Mimori, Koshi and Yoshizumi, Tomoharu},
  title = {Copy Number–Driven COX19 Promotes Colorectal Cancer Growth and Represents a Potential Therapeutic Target of Olmesartan},
  journal = {Annals of Gastroenterological Surgery},
  year = {2027},
  volume = {11},
  number = {1},
  doi = {10.1002/ags3.70303}
}
Kostenlos starten →